Most patients who come to me after a CAC scan have the same question. The number is higher than expected, and they want to know what to do about it. That question matters more than most people realize, because the answer is not what they expect. A coronary calcium score is not a countdown. It is a data point. And data points exist to inform action.
The science behind this test is robust. Data from the Multi-Ethnic Study of Atherosclerosis (MESA), a large NIH-sponsored prospective study, established that CAC scoring is one of the strongest tools we have for refining cardiovascular risk in asymptomatic individuals, often adding predictive value beyond traditional risk factors such as cholesterol and blood pressure, or any other conventional risk factor we measure.
What that means clinically is that a high score is not background noise. It is a signal worth acting on.
But here is the distinction I make with every patient who sits across from me with a concerning result: the clinical target is not reversing the number. It is changing its trajectory. MESA follow-up data from nearly 6,000 patients show that the rate of CAC progression, meaning how fast the score rises over time, is itself a predictor of future coronary heart disease events. Slowing progression is associated with a lower-risk clinical picture, and that is the goal. And for most patients who engage seriously with the options available, it is achievable.
In this article, I cover:
Know Your Cardiovascular Risk Before It Becomes a Crisis
At Elite Medical Associates, I integrate CAC scoring into a comprehensive cardiovascular risk assessment, reviewed personally, not delegated.
Explore Cardiovascular Risk Assessment →
Can You Actually Lower a Coronary Calcium Score?
This is the first question almost every patient asks. The honest answer requires a distinction that matters clinically.
Coronary artery calcium reflects calcified, stabilized atherosclerotic plaque. Once calcium deposits form in the walls of the coronary arteries, they do not typically dissolve or disappear. The raw Agatston score rarely decreases. But that is not actually the clinical target.
What the evidence shows
What an intervention can do is slow or arrest the rate of progression. The numbers are worth knowing. In serial CT scanning data, untreated patients showed coronary calcium progression averaging 52% per year. Patients on statin therapy who reached an LDL below 120 mg/dL showed net regression of their calcium volume score. Those who did not hit that target still progressed, but at 25% per year rather than 52%. Treatment intensity and LDL control directly determine how fast the score moves. That is the lever we are pulling.
Slower progression suggests a more controlled atherosclerotic process and a lower-risk clinical trajectory. That is achievable. That is what I am working toward in clinical practice.
Why trajectory matters more than the number
In general, soft, lipid-rich plaque is more prone to rupture than dense, stable calcified plaque. But total plaque burden still matters, which is why CAC must be interpreted in a clinical context. A rising CAC score reflects active disease. A static or slowly progressing score, achieved through deliberate intervention, is a fundamentally different and better clinical picture.
The goal is trajectory control. And for most patients who engage seriously with the options available, that goal is within reach.
What does a high coronary calcium score mean?
A high coronary calcium score means there is calcified plaque in the walls of your coronary arteries, placing you at higher risk of heart disease and cardiac events. The scan measures calcified plaque in the coronary arteries and helps estimate future cardiovascular risk when interpreted alongside your age, symptoms, risk factors, and medical history. A high score is not a diagnosis of imminent danger. It is a clinical signal that the time to act is now, before symptoms develop.
Lifestyle Changes: The Foundation of Any Serious Plan
Lifestyle modification is not a soft alternative to medical treatment. For patients with elevated coronary artery calcium, it is a foundational component of the clinical plan, working alongside pharmacological management, not instead of it.
Exercise as medicine
Regular aerobic exercise is among the most well-supported interventions for reducing the risk of cardiovascular disease events in patients with existing coronary artery calcium. The mechanisms are multiple: improved endothelial function, lower blood pressure, better insulin sensitivity, and reduced systemic inflammation all contribute to slowing atherosclerosis.
The American Heart Association recommends a minimum of 150 minutes of moderate-intensity aerobic activity weekly. In my practice, I treat exercise as a prescription with a specific dose and rationale, not a general wellness recommendation.
Smoking and metabolic health
Smoking is a direct driver of endothelial damage and accelerated atherosclerosis. For any patient with a high calcium score who still smokes, cessation is the single highest-priority intervention. There is no cardiovascular medication that offsets continued smoking at a meaningful level.
Metabolic factors, particularly insulin resistance, visceral adiposity, and sleep apnea, accelerate coronary artery disease through chronic low-grade inflammation and lipid dysregulation. These are central cardiovascular risk factors. I address them explicitly in every patient with a high CAC score, not as side concerns but as primary drivers of risk.
What Dissolves Calcium Deposits in the Arteries: Diet and Food
I want to be direct about this: no food dissolves established calcium deposits in the coronary arteries. That framing sets an expectation that does not match the biology. What dietary change can do is meaningfully slow the processes that drive further calcium buildup and atherosclerotic progression. That distinction matters, and I make it with every patient.
What foods reduce calcium score progression
The Mediterranean-pattern diet has the strongest and most consistent evidence base for cardiovascular risk reduction in patients with established atherosclerosis risk factors. The components with the best data include:
Fatty fish (salmon, mackerel, sardines): Rich in omega-3 fatty acids, which reduce triglycerides, lower systemic inflammation, and support endothelial function. Consistent intake supports triglyceride control, endothelial function, and a heart-healthy dietary pattern.
Extra-virgin olive oil: The primary fat source in the Mediterranean diet, associated with reduced LDL oxidation and lower cardiovascular event rates across landmark trials, including PREDIMED.
Leafy greens (spinach, kale, arugula): High in vitamin K1, which plays a role in calcium metabolism and may reduce vascular calcification. Also high in nitrates, which support nitric oxide production and vascular tone.
Walnuts and almonds: Associated with improved lipid profiles and reduced inflammatory markers. Walnuts carry a particularly favorable omega-3 to omega-6 ratio.
Legumes: High fiber content supports LDL reduction and glycemic control, both of which slow plaque development in the coronary arteries.
The dietary patterns most consistently associated with accelerated atherosclerosis include high intake of refined carbohydrates, ultra-processed foods, and added sugars. These drive insulin resistance, raise triglycerides, and increase small dense LDL particles, all of which contribute to plaque buildup and cardiovascular disease risk.
The vitamin K2 question
Vitamin K2 (specifically MK-7) has attracted genuine scientific interest in the context of vascular calcification. The mechanism is biologically plausible: K2 activates matrix Gla-protein, which inhibits calcium deposition in arterial walls. The Rotterdam Study and related cohort data support an association between higher K2 intake and reduced arterial stiffness.
The evidence in humans is promising but not yet definitive enough to call K2 a proven treatment for reducing coronary artery calcium. This is an area I follow closely. I integrate K2 into individual plans where the clinical context supports it, with appropriate expectations set. It is found in fermented foods such as natto and aged cheeses, and is also available as a supplement.
If you have a high calcium score and are considering K2, that conversation belongs with your physician, not with a supplement brand.
Patients taking warfarin or other vitamin K-sensitive anticoagulants should not start vitamin K2 without physician guidance.
What dissolves calcium deposits in the body?
No substance, dietary or otherwise, has been shown to dissolve established calcium deposits in the coronary arteries. Calcium in arterial plaque is structurally embedded, not free-floating. What certain interventions and sustained dietary pattern changes can do is slow the process of further calcification and reduce overall cardiovascular risk. Any product claiming to dissolve arterial calcium deposits should be viewed with significant skepticism.
Supplements to Lower Calcium Score: What Has Actual Evidence
Supplementation is discussed frequently in the context of coronary calcium. The evidence varies considerably by compound, and I think patients deserve an honest assessment rather than a list of products with caveats buried at the bottom.
Omega-3 fatty acids
Prescription-strength omega-3s, specifically icosapentaenoic acid (EPA), have demonstrated cardiovascular event reduction in high-risk patients with elevated triglycerides.
In appropriately selected high-risk patients with elevated triglycerides already on statin therapy, the REDUCE-IT trial showed a 25% relative reduction in major cardiovascular events with high-dose EPA. That is not marginal data. It represents one of the more significant pharmacological findings in cardiovascular risk reduction in the past decade.
Over-the-counter fish oil varies significantly in quality, EPA/DHA ratio, and oxidation status. At Elite Medical Associates, I use prescription-grade formulations where indicated, not general retail products.
Vitamin D
Vitamin D deficiency is prevalent in patients with heart disease and is associated with increased risk of heart attacks and stroke. Optimizing vitamin D status is a standard component of any thorough cardiovascular risk assessment. Supplementation alone does not lower a calcium score, but correcting deficiency supports the broader metabolic environment in which plaque progression occurs. Our comprehensive review on vitamin D and its clinical significance covers this in detail.
Magnesium
Magnesium plays a regulatory role in vascular smooth muscle function and calcium transport. Low magnesium is associated with increased arterial calcification in several observational studies. The evidence for supplementation specifically reducing coronary artery calcium is not conclusive, but correcting magnesium insufficiency is clinically reasonable in patients with elevated cardiovascular risk, particularly those with insulin resistance or high blood pressure.
A word of caution
A number of products are marketed with claims about dissolving calcium deposits or clearing plaque from the arteries. None have robust clinical trial data supporting those claims. EDTA chelation therapy, for example, remains controversial and is not a standard-of-care intervention for elevated coronary calcium scores outside of specific research protocols.
Decisions about supplementation in this context should be made with a physician who has reviewed your complete clinical picture, not based on what is being sold as a solution to coronary artery disease.
Medical Management: What Actually Gets Prescribed
Lifestyle and dietary changes are foundational. For many patients with a clearly elevated CAC score, particularly those above 100, pharmacological management is also indicated. The two work together. One does not replace the other.
Statins and lipid optimization
High-intensity statin therapy is typically the primary pharmacological intervention for elevated coronary artery calcium scores. Statins lower LDL cholesterol and appear to stabilize existing atherosclerotic plaque, reducing the likelihood of rupture and thrombosis.
There is a nuance here that I find myself explaining regularly: statins can paradoxically increase the measured CAC score while actually improving outcomes. The reason is that they promote calcification of previously soft, more dangerous plaque. A higher CAC score after statin initiation does not automatically mean treatment failure. In some cases, it may reflect plaque stabilization rather than worsening risk. This matters enormously in how we interpret serial scans.
How is coronary artery calcification diagnosed and treated?
Coronary artery calcification is diagnosed through a non-invasive CT scan that measures the amount of calcium deposited in the coronary arteries. A physician interprets the result alongside your full risk profile. Treatment focuses on slowing progression rather than reversing existing deposits. That typically means high-intensity statin therapy, blood pressure control, and heart-healthy lifestyle changes, all working together to reduce your risk of a cardiovascular event.
Advanced lipid biomarkers beyond standard cholesterol
Standard LDL does not capture the full picture of cardiovascular risk. ApoB, lipoprotein (a), and small dense LDL particle number provide substantially more predictive information, particularly in patients at borderline risk on a standard lipid panel.
Two patients can have identical LDL levels and completely different coronary calcium scores. That gap is precisely why I order advanced biomarkers routinely.
For patients with elevated Lp(a), a genetically determined lipoprotein associated with increased cardiovascular risk, targeted management is available and needs to be discussed explicitly.
Blood pressure and metabolic control
Targeting systolic blood pressure below 130 mmHg in patients with elevated coronary calcium scores is well-supported by evidence. Antihypertensive therapy, particularly ACE inhibitors and ARBs, has demonstrated benefits beyond blood pressure reduction alone, including direct effects on vascular remodeling.
Metabolic optimization, including glycemic control and management of insulin resistance, is equally important for reducing the risk of further plaque progression. Our metabolic optimization program addresses these drivers directly and systematically.
How I Approach a High Calcium Score at Elite Medical Associates
A CAC result does not leave my office as a number on a printout. It becomes the opening of a clinical conversation, and that conversation covers considerably more than a single scan.
At Elite Medical Associates, an elevated coronary calcium score triggers a structured, comprehensive cardiovascular risk assessment. That means advanced lipid biomarkers, not just a standard cholesterol panel. It means ApoB, Lp(a), and inflammatory markers like hsCRP. It means a full metabolic review, a detailed look at blood pressure patterns, insulin resistance, sleep, body composition, and every modifiable risk factor that could be accelerating what the scan has already detected. Nothing is treated as background noise. Everything is evaluated in the context of the whole patient.
The difference in preventive medicine is that we have something critical care almost never has: time. When a patient comes to me with a coronary calcium score of 300, no symptoms, and a decade ahead of them to change what happens next, that is not a crisis. That is an opportunity. The data are telling us something important before the body has to.
That is the whole point of this work. A high calcium score in the right hands, interpreted with the right context, and acted on with the right plan, is not a sentence. It is a head start.
Schedule a Cardiovascular Risk Assessment
CAC scoring interpreted in full clinical context, not in isolation. Direct physician access with Dr. Sharma.